Radiopeptide therapy with cholecystokinin -B/gastrin receptor ligands Toxicity and therapeutic efficacy of Auger electron- versus alpha- or beta-emitters
Behr, T.M.; Kluge, G.; Behe, M.P.
Proceedings of the American Association for Cancer Research 44: 24
2003
ISSN/ISBN: 0569-2261 Accession: 035605082
PDF emailed within 1 workday: $29.90
Related References
Behr, T.M.; Behe, M.; Angerstein, C.; Becker, W. 2000: Radiopeptide therapy with cholecystokinin-B /gastrin receptor ligands Dose-limiting toxicity and therapeutic efficacy of Auger/conversion electron versus alpha or conventional beta emitters Cancer Biotherapy and Radiopharmaceuticals 15(4): 399Behr, T.M.; Behe, M.P.; Angerstein, C.; Roesch, F.; Becker, W. 2001: Radiopeptide therapy with cholecystokinin -B/gastrin receptor ligands Toxicity and therapeutic efficacy of Auger e- versus alpha or beta emitters Journal of Nuclear Medicine 42(5 Suppl): 68P
Behr, T.M.; Behe, M.P. 2003: Radiopeptide therapy with gastrin receptor ligands Toxicity and therapeutic efficacy of alpha, Auger electron and beta emitters Abstracts of Papers American Chemical Society 225(1-2): NUCL 114
Behr, T.M.; Behe, M.; Angerstein, C.; Stabin, M.G.; Apostolidis, C.; Molinet, R.; Koch, L.; Roesch, F.; Becker, W. 2000: Radiopeptide therapy with cholecystokinin -B/gastrin receptor ligands labeled with Auger/conversion electron- versus alpha- or conventional beta-emitters Journal of Nuclear Medicine 41(5 Suppl): 112P
Behr, T.M.; Behe, M.; Loehr, M.; Angerstein, C.; Becker, W. 1999: Therapeutic efficacy and toxicity of auger/conversion-electron versus beta-emitters in radioimmunotherapy with internalizing antibodies Journal of Nuclear Medicine 40(5 Suppl): 313P
Behr, T.M.; Memtsoudis, S.; Vougioukas, V.; Gratz, S.; Nebendahl, K.; Becker, W. 1997: Therapeutic efficacy and dose-limiting toxicity of auger electron versus beta emitters in radioimmunotherapy of colorectal cancer with internalizing antibodies Journal of Nuclear Medicine 38(5 Suppl): 7P
Behr, T.M.; Sgouros, G.; Vougiokas, V.; Memtsoudis, S.; Gratz, S.; Schmidberger, H.; Blumenthal, R.D.; Goldenberg, D.M.; Becker, W. 1998: Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model International Journal of Cancer 76(5): 738-748
Govindan, S.V.; Goldenberg, D.M.; Elsamra, S.E.; Griffiths, G.L.; Ong, G.L.; Brechbiel, M.W.; Burton, J.; Sgouros, G.; Mattes, M.J. 2000: Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 41(12): 2089-2097
Behr, T.M.; Behe, M.; Stabin, M.G.; Wehrmann, E.; Apostolidis, C.; Molinet, R.; Koch, L.; Goldenberg, D.M.; Becker, W. 1999: Experimental studies on the therapeutic efficacy and toxicity of alpha- as compared to beta-emitters in radioimmunotherapy Journal of Nuclear Medicine 40(5 Suppl): 313P
Behr, T.M.; Sgouros, G.; Stabin, M.G.; Béhé, M.; Angerstein, C.; Blumenthal, R.D.; Apostolidis, C.; Molinet, R.; Sharkey, R.M.; Koch, L.; Goldenberg, D.M.; Becker, W. 1999: Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 5(10 Suppl): 3031s-3043s
Berna, M.J.; Tapia, J.A.; Sancho, V.; Jensen, R.T. 2007: Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential Current Opinion in Pharmacology 7(6): 583-592
Behr, T.M.; Sgouros, G.; Stabin, M.G.; Behe, M.; Angerstein, C.; Blumenthal, R.D.; Apostolidis, C.; Molinet, R.; Sharkey, R.M.; Koch, L.; Goldenberg, D.M.; Becker, W. 1999: Factors influencing the radiation-induced myelotoxicity of beta-, Auger/conversion electron-, or alpha-emitters Journal of Nuclear Medicine 40(5 Suppl): 314P
Runge, R.; Oehme, L.; Kotzerke, J.ör.; Freudenberg, R. 2016: The effect of dimethyl sulfoxide on the induction of DNA strand breaks in plasmid DNA and colony formation of PC Cl3 mammalian cells by alpha-, beta-, and Auger electron emitters (223)Ra, (188)Re, and (99m)Tc Ejnmmi Research 6(1): 48
Behr, T.M.; Béhé, M.; Stabin, M.G.; Wehrmann, E.; Apostolidis, C.; Molinet, R.; Strutz, F.; Fayyazi, A.; Wieland, E.; Gratz, S.; Koch, L.; Goldenberg, D.M.; Becker, W. 1999: High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model Cancer Research 59(11): 2635-2643
Behr, T.M.; Béhé, M.P. 2002: Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies Seminars in Nuclear Medicine 32(2): 97-109
Schmitz, F.; Pratt, D.S.; Wu, M.J.; Kolakowski, L.F.; Beinborn, M.; Kopin, A.S. 1996: Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor Molecular Pharmacology 50(2): 436-441
Reissig, F.; Wunderlich, G.; Runge, R.; Freudenberg, R.; Lühr, A.; Kotzerke, J.ör. 2020: The effect of hypoxia on the induction of strand breaks in plasmid DNA by alpha-, beta- and Auger electron-emitters 223Ra, 188Re, 99mTc and DNA-binding 99mTc-labeled pyrene Nuclear Medicine and Biology 80-81: 65-70
Kalindjian, S.B.; Buck, I.M.; Linney, I.D.; Wright, P.T.; Mcdonald, I.M.; Steel, K.I. Mary; Hull, R.A. David; Roberts, S.P.; Gaffen, J.D.; Vinter, J.G.; Walker, M.K.; Black, J.W.; Watt, G.F.; Harper, E.A. 2002: Gastrin and cholecystokinin receptor ligands Official Gazette of the United States Patent and Trademark Office Patents 1264(2)
Behr, T.M.; Behe, M.; Stabin, M.G.; Molinet, R.; Apostolidis, C.; Koch, L.; Becker, W. 1999: Radioimmunotherapy with alpha-emitters Therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab in a human colonic cancer model Proceedings of the American Association for Cancer Research 40: 644
Bock, M.G.; DiPardo, R.M.; Evans, B.E.; Rittle, K.E.; Whitter, W.L.; Veber, D.E.; Anderson, P.S.; Freidinger, R.M. 1989: Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260 Journal of Medicinal Chemistry 32(1): 13-16